Institut National De La Sante Et De La Recherche Medicale

University of Utah Research Foundation

Other

Sanofi

Agence Nationale De Valorisation De La Recherche (anvar)

Univ. of Utah Research Foundation

Centre National De La Recherche Scientifique

Université Paris Descartes

Pierre Corvol

Florent Soubrier

Jean-Marc Lalouel

Richard P Lifton

Xavier Jeunemaitre

Youri Kotelevtsev

Bernard P Roques

Catherine Llorens-Cortes

Christine Hubert

Marie-Claude Fournie-Zaluski

Genevieve Evin

Francois Alhenc-Gelas

Vincent Dive

Joseph Diaz

Athanasios Yiotakis

Jean-Pierre Gagnol

Remy Guegan

Catherine Cazaubon

Philippe Cuniasse

Nicolas Inguimbert

Bertrand Castro

Jo&euml;l Menard

Jo&euml;l Cotton

Joel Menard

Marie-Th&eacute;r&egrave;se Chauvet

Eric Ezan

Annie Michaud

Bernard Castro

Marie-Claude Fourni&eacute;-Zaluski

The invention relates to derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfonates) of formula (1), of use for the treatment and prevention of primary and secondary arterial hypertension.

Derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfonates) and compositions comprising the same

The invention relates to the bis-hydrochloride of 4,4'-dithiobis-(3-aminobutane-1-sodium sulphonate) and the bis-trifluoracetate of 4,4&#x2032;-dithiobis-(3-aminobutane-1-sulphonate of 2,2-dimethylpropyl). The invention also relates to a pharmaceutical composition comprising one of said compounds and to the use of one of said compounds for the production of a medicament. The invention is suitable for use in a treatment method for hypertension and indirectly- or directly-linked illnesses.

Derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same

N-terminal site selective inhibitors of human angiotensin conversion enzyme (ACE)

The invention relates primarily to a pharmaceutical composition which can be used for lowering arterial blood pressure and is characterized in that it contains as active ingredient at least one selective aminopeptidase A inhibitor. Said inhibitor can notably be (S) 3-amino-4-mercaptobutyl sulfonic acid or one of its salts.

Pharmaceutical composition comprising at least one aminopeptidase A inhibitor

The association of the molecular variant G-6A of the angiotensinogen gene with human hypertension is disclosed. The determination of this association enables the screening of persons to identify those who have a predisposition to high blood presure.

Method to determine predisposition to hypertension

The association of the molecular variant G-6A of the angiotensinogen gene with human hypertension is disclosed. The determination of this association enables the screening of persons to identify those who have a predisposition to high blood pressure.

Agents and procedures for the study of the genetic polymorphism of the

The association of molecular variants of the angiotensinogen gene with human essential hypertension is disclosed. The determination of this association enables the screening of persons to identify those who have a predisposition to high blood presure.

Angiotensinogen gene variants and predisposition to hypertension

The invention relates to the cloning and sequencing of the nucleic acid coding for the human ACE as well as the determination of the peptide chain corresponding to the ACE and of active peptide fragments which derive from it. Another subject of the invention is the utilization of the above-mentioned polypeptides for the implementation of in vitro diagnostic methods for hypertension and for the design of new inhibitors of the ACE. The invention also relates to the utilization of the nucleotide probes of the invention for the in vitro screening of the polymorphisms of the gene coding for the ACE.

Nucleic acid coding for the human angiotensin converting enzyme (ACE),

The present invention relates to peptide derivatives of the general formula:

Acid-protease inhibiting peptide derivatives

The novel derivatives of pepstatin have the general formula (I) below in which X, Y and Z, are identical or different, and each represent an amino-acid selected from arginine, glutamic acid, aspartic acid, lysine, histidine and valine, the carboxyl function of the terminal amino-acid being esterifiable. The indices a, b and c are each equal to zero or 1, the sum a+b+c being equal to 1, 2 or 3. The invention also includes the water soluble salts and their preparation, and the compositions containing them. ##STR1## These novel products are particularly useful in the diagnosis and treatment of arterial hypertension due to the action of renine.

Novel derivatives of pepstatin, their preparation and compositions

Growing community of inventors

Paris, France

Pierre Corvol